Latest News and Press Releases

NEW YORK and BASEL, Switzerland, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu,...

Transition of small molecule expertise to Arvelle completes transformation of Axovant into a company focused exclusively on gene therapiesAxovant will receive a preferred equity stake in Arvelle,...

Expanded pipeline with two investigational gene therapy programs licensed from the University of Massachusetts Medical School for the treatment of GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases ...

Axovant’s CEO, Pavan Cheruvu, M.D., will be presenting at the J.P. Morgan Healthcare Conference at 8:00 a.m. PST on Thursday, January 10th, 2019Initial clinical data expected in first half of 2019...

BASEL, Switzerland, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares...

BASEL, Switzerland, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of...

Two novel programs for fatal pediatric diseases deepen Axovant’s neurological gene therapy pipelineAXO-AAV-GM1 expected to enter the clinic in first half 2019, with initial data expected in second...

Primary efficacy endpoint assessed by sleep laboratory video assessment was not metAxovant is discontinuing clinical development of nelotanserin  BASEL, Switzerland, Dec. 10, 2018 (GLOBE NEWSWIRE)...

Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PDConfirmed with FDA that the...

Greg MacMichael, Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis, joins Axovant as SVP of technical operationsParag Meswani, Pharm.D., formerly...